Roundys, FX Allianc...
Health Care: Drugs
ViroPharma Inc. (VPHM: NASDAQ)
$30.32 0.00 | -0.02%
02/09/12 - 12:50 PM ET
342.18K / 1.21M
Vol / Avg. Vol:30.52 / 30.32
Open / Prev. Close:30.27 - 30.77
Today's Range:14.62 - 31.00
52 Wk Range:10.70%
Performance YTD:TheStreet Rating:
Portfolios with VPHM
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks At New 52-Week Highs...
- UserStocks
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorEarnings Short Squeeze Play...
- ContributorMarket Leading Stocks 03-09...
- UserOpen in TS
- ContributorBreakout Stocks Of The Week...
- UserPART 5 JPMorgan 28th Annual...
Latest VPHM Headlines from TheStreet
- Sifting Through Small-Caps for Acquisition Targets 01.27.12 | 05:01 pm
- ViroPharma Reaches New 52-Week High (VPHM) 01.17.12 | 03:01 pm
- 8 Stocks Hitting New Highs Today 01.06.12 | 12:01 pm
- ViroPharma Reaches New 52-Week High (VPHM) 01.06.12 | 08:01 am
- Vical, RF Micro: After-Hours Trading 01.05.12 | 06:01 pm
- Analysts' Actions: NFLX, AA, MU, KMX 12.22.11 | 10:12 am
- Analysts' Actions: GRPN, VRUS, MU, CVC 12.19.11 | 09:12 am
- ViroPharma Reaches New 52-Week High (VPHM) 12.14.11 | 03:12 pm
- ViroPharma Stock Hits New 52-Week High (VPHM) 12.02.11 | 08:12 am
- ViroPharma Stock Hits New 52-Week High (VPHM) 11.23.11 | 02:11 pm
Press Releases for VPHM
- ViroPharma Provides Update On Industrial Scale Supplement For Cinryze® (C1 Esterase Inhibitor [Human]) - PR Newswire 02.07.12 | 07:02 am
- Health Canada Grants Priority Review Status For New Drug Submission (NDS) For Cinryze⢠(C1 Inhibitor [human]) - PR Newswire 01.13.12 | 07:01 am
- ViroPharma Provides 2012 Outlook - PR Newswire 01.05.12 | 04:01 pm
- ViroPharma Announces Appointment Of Julie H. McHugh To Board Of Directors - PR Newswire 01.03.12 | 04:01 pm
- ViroPharma Purchases Exclusive Option To Acquire Meritage Pharma - PR Newswire 12.22.11 | 06:12 pm
- ViroPharma Announces Approval Of Modernized Labeling For Vancocin® (vancomycin Hydrochloride, USP) Capsules - PR Newswire 12.14.11 | 02:12 pm
- ViroPharma And Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [human]) With Hyaluronidase (rHuPH20) - PR Newswire 12.06.11 | 08:12 am
- ViroPharma To Participate In Two December Healthcare Investor Conferences - PR Newswire 12.05.11 | 10:12 am
- ViroPharma Completes Acquisition Of DuoCort Pharma AB - PR Newswire 11.15.11 | 08:11 am
- DuoCort Pharma's Orphan Drug Plenadren® Granted European Marketing Authorization For Adrenal Insufficiency - PR Newswire 11.07.11 | 07:11 am
Partner Headlines for VPHM
- Priority Review for VPHM's Drug - Analyst Blog - Zacks 01.16.12 | 10:01 am
- 10 Stocks That Made New Highs On Friday: Hedging Costs - Seeking Alpha 01.15.12 | 07:01 am
- 12 Stocks for 2012 - Investment Ideas - Zacks 01.13.12 | 01:01 am
- Company News for January 9, 2012 - Corporate Summary - Zacks 01.09.12 | 10:01 am
- ViroPharma Expects a Strong 2012 - Analyst Blog - Zacks 01.06.12 | 05:01 pm
- ViroPharma Sees 2012 Sales of $600-660M vs $593M Est - Benzinga 01.05.12 | 04:01 pm
- ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors - Benzinga 01.03.12 | 04:01 pm
- ViroPharma Is Poised For Gain - Seeking Alpha 01.01.12 | 09:01 am
- UPDATE: Bank of America Reiterates Buy, Raises PT to $32 on ViroPharma - Benzinga 12.15.11 | 09:12 am
- ViroPharma's Seizure Drug Reaches UK - Analyst Blog - Zacks 12.14.11 | 10:12 am
